Tokyo

London

New York

finscreener facebook fan page

finscreener twitter page

Register

Sign In

EUR/USD

1.1789

-0.0047

-0.40%

GBP/USD

1.3430

0.0019

0.14%

USD/JPY

112.25

-0.4770

-0.42%

USD/CHF

0.9876

0.0022

0.22%

EUR/GBP

0.8778

-0.0048

-0.55%

USD/CAD

1.2753

-0.0063

-0.49%

NZD/USD

0.6988

-0.0030

-0.43%

EUR/JPY

132.33

-1.0980

-0.82%

EUR/CHF

1.1642

-0.0021

-0.18%

Sage Therapeutics Inc

NASDAQ: SAGEHealthcare / Biotechnology / USA
159.98-4.67-2.84%Vol 740 1091Y Perf 223.61%
Dec 14th, 2017 15:38
BID159.78 ASK159.98
Open164.36 Previous Close164.65
Pre-Market- After-Trading164.00
 - -%  -0.65 -0.39%
Target Price
164.00 
Analyst Rating
Strong Buy 1.08
Potencial %
2.80 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/-100 
Income Ranking
 —    -
Market Cap (mil)6 567 
Earnings Rating
Price Range Ratio 52wk %
89.61 
Earnings Date

Today's Price Range

155.06164.36

 

52wk Range

44.55173.36

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Month
73.96%
3 Months
133.98%
6 Months
110.15%
1 Year
223.61%
3 Years
362.89%
5 Years
-
Last Quotes
Name / TickerPriceChg.Chg.%
SAGE159.98-4.6700-2.84
AAPL172.340.07000.04
GOOG1 049.038.42000.81
MSFT84.88-0.4700-0.55
XOM83.05-0.0700-0.08
WFC59.540.14000.24
JNJ141.92-0.9700-0.68
FB178.770.47000.26
GE17.69-0.0700-0.39
JPM105.09-0.4200-0.40
...

TickerPriceChg.%52 Week High
FOXA34.856.4135.15
FOX34.155.6034.35
MAT16.385.0731.60
TIF99.313.34100.80
DIS110.933.09116.10
DAL55.222.9655.75
STZ223.782.38227.20
WMB29.712.2432.69
EQIX459.711.87495.35
CBS58.231.8570.10
MCK157.941.76169.29
COP52.551.6854.22
CMCSA39.231.6842.18
Financial StrengthValueIndustryS&P 500US Markets
Quick Ratio 4.90
Current Ratio 5.00
Long Term Debt to Total Capital -
Total Debt to Equity -
Interest Coverage -
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
Gross Margin-
EBIT Margin-
EBITDA Margin-
Pre-tax Profit Margin-
Profit Margin-
ValuationValueIndustryS&P 500US Markets
PE Ratio -
PB Ratio 19.34
PS Ratios -
Price to Cash Flow -
Price to Free Cash Flow -17.90
Cash Flow Per Share -5.20
Price to Tangible Book17.45
Book Value per Share4.81
Enterprise Value (in ths.)3 600 480
Management EffectivenessValueIndustryS&P 500US Markets
Return on Equity (5Y Avg)-49.94
ROE last 12 Months -81.18
Return on Assets (5Y Avg) -19.18
ROA last 12 Months -72.61
Return on Capital (5Y Avg) -
ROC last 12 Months -83.61
Return on invested Capital Q -32.03
Return on invested Capital Y-58.64
Assets Turnover-
Receivables Turnover-
RevenueValueIndustryS&P 500US Markets
Revenue LTM (in ths.)-
Revenue per Share -
Revenue Growth 3 Years -
Revenue Growth 5 Years -
DividendsValueIndustryS&P 500US Markets
Dividend Yield -
Dividend Rate -
Dividend Growth 3 Years-
Dividend Growth 5 Years-

Earnings HistoryEstimateReportedSurprise %
Q03 2017-1.95-1.97-1.03
Q02 2017-1.67-1.88-12.57
Q01 2017-1.56-1.522.56
Q04 2016-1.14-1.50-31.58
Q03 2016-1.16-1.150.86
Q02 2016-1.04-1.08-3.85
Q01 2016-0.97-0.970.00
Q04 2015-0.91-0.99-8.79
Earnings Per EndEstimateRevision %Trend
12/2017 QR-2.03-7.98Negative
12/2017 FY-7.40-1.79Negative
3/2018 QR-1.990.00-
12/2018 FY-7.71-9.52Negative
Next Report Date2nd Nov 2017
Estimated EPS Next Report-1.95
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume740 109
Shares Outstanding (in ths.)41 050
Trades Count3 450
Dollar Volume671 834 159
Avg. Volume599 154
Avg. Weekly Volume2 875 829
Avg. Monthly Volume1 473 612
Avg. Quarterly Volume1 042 558

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

100%0%

Bearish Bullish

54%46%

Bearish Bullish

69%31%

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (91.67 %)
10 (76.92 %)
8 (72.73 %)
Moderate Buy
1 (8.33 %)
1 (7.69 %)
1 (9.09 %)
Hold
0 (0.00 %)
2 (15.38 %)
2 (18.18 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.08
Strong Buy
1.38
Strong Buy
1.45

There are no comments yet.

News

x